- Home
- WHF vs SGMT Comparison
WHF vs SGMT Comparison
Compare WHF & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | WHF | SGMT |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.2M | 169.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | WHF | SGMT |
|---|---|---|
| Price | $7.17 | $4.81 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $7.75 | ★ $26.38 |
| AVG Volume (30 Days) | 130.8K | ★ 309.3K |
| Earning Date | 03-02-2026 | 03-11-2026 |
| Dividend Yield | ★ 14.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4,523.58 |
| P/E Ratio | $15.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.07 | $1.73 |
| 52 Week High | $9.95 | $11.41 |
Technical Indicators
Market Signals| Indicator | WHF | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 54.52 | 36.00 |
| Support Level | $6.87 | N/A |
| Resistance Level | $7.24 | $6.62 |
| Average True Range (ATR) | 0.22 | 0.27 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 56.05 | 13.89 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.